MedTrace Logo

Adjuvant Aflibercept for Metastatic Colorectal Cancer

NCT01669720 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment. The study will also look at the side effects of aflibercept and the effect on quality of life.

Conditions

Interventions

DRUG

Aflibercept

Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years

Sponsors & Collaborators

  • Rhode Island Hospital

    collaborator OTHER

  • The Miriam Hospital

    collaborator OTHER

  • Lifespan

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • Montefiore Medical Center

    collaborator OTHER

  • University of Florida

    collaborator OTHER

  • Sanofi

    collaborator INDUSTRY

  • Brown University

    lead OTHER

Principal Investigators

  • Howard Safran, MD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01669720 on ClinicalTrials.gov